Search results for "PROGRESS"

showing 10 items of 1620 documents

Subclinical and clinical atherosclerosis in rheumatoid arthritis: results from the 3-year, multicentre, prospective, observational GIRRCS (Gruppo Ita…

2019

Background Rheumatoid arthritis (RA) is associated with an increased risk of morbidity and mortality, when compared with general population, largely due to enhanced atherosclerotic disease. In this work, we aimed at assessing both occurrence and predictive factors of subclinical and clinical atherosclerosis in RA. Methods From January 1, 2015, to December 31, 2015, consecutive participants with RA, admitted to Italian Rheumatology Units, were assessed in the GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) cohort. After that, those participants were followed up in a 3-year, prospective, observational study, assessing the occurrence of subclinical and clinical ather…

0301 basic medicineMaleTime Factorslcsh:Diseases of the musculoskeletal systemType 2 diabetesComorbidityArthritis Rheumatoid0302 clinical medicineProspective StudiesSubclinical infectionAged 80 and overeducation.field_of_studyIncidence (epidemiology)IncidenceAge FactorsType 2 diabetesMiddle AgedPrognosisCardiovascular diseaseSurvival RateCardiovascular diseasesItalyRheumatoid arthritisAtherosclerosiCohortDisease ProgressionFemaleResearch ArticleAdultmedicine.medical_specialtyRemissionPopulation03 medical and health sciencesYoung AdultAge DistributionSex FactorsInternal medicinemedicineHumansSex DistributionRheumatoid arthritiseducationRheumatoid arthritiAged030203 arthritis & rheumatologybusiness.industryAtherosclerosis; Cardiovascular diseases; Remission; Rheumatoid arthritis; Type 2 diabetesmedicine.diseaseAtherosclerosisRheumatologySettore MED/16 - Reumatologia030104 developmental biologyBlood pressurelcsh:RC925-935businessFollow-Up Studies
researchProduct

Malignant ovarian germ cell tumors in pediatric patients: The AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) study.

2017

Objective Malignant ovarian germ cell tumors (MOGCT) carry an excellent prognosis, and the treatment aims to achieve results with the least possible treatment-related morbidity. The aim of this study was to assess the outcomes of pediatric patients with MOGCT. Methods Patients were treated according to their stage: surgery and surveillance for stage I; a modified bleomycin–etoposide–cisplatin (BEP) regimen for stages II (three cycles), III, and IV (three cycles) with surgery on residual disease. Results Seventy-seven patients were enrolled (median age 11.8 years), 26 with dysgerminoma (Dysg), 13 with immature teratoma and elevated serum alpha-fetoprotein levels (IT + AFP), and 38 with nondy…

0301 basic medicineMalechildhood; germ cell tumors; ovarianGastroenterology0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineProspective StudiesStage (cooking)germ cell tumorsProspective cohort studyChildEtoposideOvarian NeoplasmsHematologychildhood germ cell tumors ovarianNeoplasms Germ Cell and EmbryonalPrognosisCombined Modality TherapySurvival RateOncology030220 oncology & carcinogenesisChild PreschoolFemalemedicine.medical_specialtyAdolescentOvariectomy03 medical and health sciencesBleomycinInternal medicineDysgerminomaovarianHumansSurvival ratechildhoodNeoplasm Stagingbusiness.industrySettore MED/20 - Chirurgia Pediatrica E InfantileInfantmedicine.diseaseSurgeryRegimen030104 developmental biologyPediatrics Perinatology and Child HealthSettore MED/20Immature teratomaGerm cell tumorsCisplatinbusinessProgressive diseaseFollow-Up StudiesPediatric bloodcancer
researchProduct

A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or l…

2019

Abstract Background Claudin 18.2 (CLDN18.2) is physiologically confined to gastric mucosa tight junctions; however, upon malignant transformation, perturbations in cell polarity lead to CLDN18.2 epitopes being exposed on the cancer cell surface. The first-in-class monoclonal antibody, zolbetuximab (formerly known as IMAB362), binds to CLDN18.2 and can induce immune-mediated lysis of CLDN18.2-positive cells. Patients and methods Patients with advanced gastric, gastro-oesophageal junction (GEJ) or oesophageal adenocarcinomas with moderate-to-strong CLDN18.2 expression in ≥50% of tumour cells received zolbetuximab intravenously every 2 weeks for five planned infusions. At least three patients …

0301 basic medicineMalemedicine.medical_specialtyCLDN18.2Drug-Related Side Effects and Adverse ReactionsEsophageal NeoplasmsNauseagastro-oesophageal junction adenocarcinomaMedizinAdenocarcinomaGastroenterology03 medical and health sciences0302 clinical medicineStomach NeoplasmsInternal medicineGastrointestinal TumorsmedicineHumansProgression-free survivalAgedbusiness.industryStomachgastric cancerCancerAntibodies MonoclonalHematologyOriginal ArticlesMiddle Agedmedicine.diseaseddc:IMAB362030104 developmental biologymedicine.anatomical_structureTreatment OutcomeOncologyTolerability030220 oncology & carcinogenesisCohortVomitingAdenocarcinomaFemaleEsophagogastric Junctionmedicine.symptomzolbetuximabNeoplasm Recurrence Localbusiness
researchProduct

Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial

2020

[Background] Solitary fibrous tumour is an ultra-rare sarcoma, which encompasses different clinicopathological subgroups. The dedifferentiated subgroup shows an aggressive course with resistance to pazopanib, whereas in the malignant subgroup, pazopanib shows higher activity than in previous studies with chemotherapy. We designed a trial to test pazopanib activity in two different cohorts of solitary fibrous tumour: the malignant-dedifferentiated cohort, which was previously published, and the typical cohort, which is presented here.

0301 basic medicineMalemedicine.medical_specialtyIndazolesPazopanib03 medical and health sciences0302 clinical medicineInternal medicinemedicineClinical endpointHumansProspective StudiesNeoplasm MetastasisProspective cohort studySurvival rateProtein Kinase InhibitorsResponse Evaluation Criteria in Solid TumorsAgedSulfonamidesPerformance statusbusiness.industryMiddle Agedmedicine.diseasePrognosisClinical trialSurvival Rate030104 developmental biologyPyrimidinesOncologyResponse Evaluation Criteria in Solid Tumors030220 oncology & carcinogenesisSolitary Fibrous TumorsFemalebusinessProgressive diseasemedicine.drugFollow-Up Studies
researchProduct

Mediterranean diet and knee osteoarthritis outcomes: A longitudinal cohort study.

2018

Objectives: Mediterranean diet has several beneficial effects on health, but data regarding the association between Mediterranean diet and knee osteoarthritis (OA) are limited mainly to cross-sectional studies. We investigated whether higher Mediterranean diet adherence is prospectively associated with lower risk of radiographic OA (ROA), radiographic symptomatic knee OA (SxOA) and pain worsening in North American people at high risk or having knee OA. Methods: Adherence to the Mediterranean diet was evaluated using a validated Mediterranean diet score (aMED), categorized in five categories (Q1 to Q5, higher values reflecting higher adherence to Mediterranean diet). Knee OA outcomes include…

0301 basic medicineMalemedicine.medical_specialtyMediterranean diet*Osteoarthritis initiative030209 endocrinology & metabolismOsteoarthritisCritical Care and Intensive Care MedicineLower riskDiet MediterraneanArticleknee osteoarthritisNew onset03 medical and health sciencessymbols.namesake0302 clinical medicine*Mediterranean diet*Knee osteoarthritis*PainInternal medicineMediterranean dietMedicineHumanspainPoisson regressionLongitudinal StudiesLongitudinal cohort030109 nutrition & dieteticsNutrition and Dieteticsbusiness.industryMiddle AgedOsteoarthritis Kneemedicine.disease*OsteoarthritisArthralgiaosteoarthritisagedKnee painOsteoarthritis InitiativeRelative risksymbolsDisease ProgressionosteoarthritiFemalemedicine.symptom*Agedbusiness
researchProduct

Lysosomal acid lipase deficiency: Expanding differential diagnosis.

2016

The differential diagnoses for metabolic liver diseases may be challenging in clinical settings, which represents a critical issue for disorders such as lysosomal acid lipase deficiency (LAL-D). LAL-D is caused by deficient activity of the LAL enzyme, resulting in the accumulation of cholesteryl esters and triglycerides throughout the body, predominately in the liver, spleen, gastrointestinal tract, and blood vessel walls. LAL-D is a progressive, multi-organ disease with early mortality and significant morbidity characterized by a combination of hepatic dysfunction and dyslipidemia. Evidence suggests LAL-D may be substantially underdiagnosed or misdiagnosed, which is critical given that dis…

0301 basic medicineMalemedicine.medical_specialtyPathologyAdolescentEndocrinology Diabetes and MetabolismDiseaseLysosomal acid lipase deficiencyBiochemistryGastroenterologyDiagnosis Differential03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicineGeneticsmedicineLysosomal storage diseaseHumansChildMolecular BiologyTriglyceridesNiemann-Pick DiseasesGaucher Diseasebusiness.industryWolman DiseaseInfantEnzyme replacement therapySterol Esterasemedicine.diseaseClinical trial030104 developmental biologyEarly DiagnosisSebelipase alfaDisease Progression030211 gastroenterology & hepatologyFemaleCholesterol EstersDifferential diagnosisbusinessDyslipidemiaMolecular genetics and metabolism
researchProduct

Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomis…

2020

Background Venetoclax is a highly selective, potent, oral BCL-2 inhibitor, which induces apoptosis in multiple myeloma cells. Venetoclax plus bortezomib and dexamethasone has shown encouraging clinical efficacy with acceptable safety and tolerability in a phase 1 trial. The aim of this study was to evaluate venetoclax plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Methods In this randomised, double-blind, multicentre, phase 3 trial, patients aged 18 years or older with relapsed or refractory multiple myeloma, an Eastern Cooperative Oncology Group performance status of 2 or less, who had received one to three previous therapies were enrolled from …

0301 basic medicineMalemedicine.medical_specialtyTime FactorsPopulationNeutropeniaPlaceboDexamethasoneBortezomib03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind MethodInternal medicineAntineoplastic Combined Chemotherapy ProtocolsClinical endpointMedicineHumansProgression-free survivaleducationAgededucation.field_of_studySulfonamidesbusiness.industryVenetoclaxBortezomibMiddle Agedmedicine.diseaseBridged Bicyclo Compounds HeterocyclicProgression-Free SurvivalVenetoclax BCL-2 inhibitor multiple myeloma Venetoclax plus bortezomib and dexamethasone030104 developmental biologyOncologychemistryTolerability030220 oncology & carcinogenesisFemalebusinessMultiple MyelomaProteasome Inhibitorsmedicine.drug
researchProduct

Great Expectations: Principal Investigator and Trainee Perspectives on Hiring, Supervision, and Mentoring

2018

A functioning mentor–trainee relationship is of high importance in academia. Discrepancies in expectations between principal investigators (PIs) and trainees are a source of misunderstandings and conflicts, endangering scientific progress and career advancement. In this pilot study, we sought to explore the expectations of PIs and trainees, providing consensus data from physician‐scientists and junior researchers who attended an educational workshop, entitled “The EASL/AASLD Masterclass,” in December 2017. Twenty‐three Masterclass attendees, comprising nine trainees (four Ph.D. candidates, five postdoctoral researchers) and 14 PIs, responded to an online survey. Both parties were asked to s…

0301 basic medicineMedical educationHepatologyWork ethicScientific progress4. EducationAcademic developmentMEDLINEMeeting Report3. Good health03 medical and health sciences030104 developmental biology0302 clinical medicinelcsh:Diseases of the digestive system. Gastroenterologylcsh:RC799-869PsychologyCompetence (human resources)030217 neurology & neurosurgeryHepatology Communications
researchProduct

On the role of cystatin C in cancer progression

2018

Cystatin C (Cyst C) is an endogenous inhibitor of lysosomal cysteine proteinases, which has been shown to play a role in several normal and pathological processes. Interestingly, a growing number of experimental and clinical studies suggest that this inhibitor also appears to be implicated in the malignant progression of various human tumors. However, the role of Cyst C in malignant diseases is still controversial as these studies have highlighted that this protein may function either as tumor suppressor or tumor promoter. The specific mechanisms underlying these opposing effects at present remain murky and are the subject of many current investigations. On the other hand, a complete knowle…

0301 basic medicineMetastasiCysteine proteinaseGeneral Biochemistry Genetics and Molecular BiologyCysteine Proteinase Inhibitorslaw.inventionMetastasisCathepsin03 medical and health sciences0302 clinical medicinelawNeoplasmsMedicineAnimalsHumansCystGeneral Pharmacology Toxicology and PharmaceuticsNeoplasm MetastasisCystatin CCancerCathepsinbiologybusiness.industryCancerProteinase inhibitorsGeneral Medicinemedicine.disease030104 developmental biologyCystatin C030220 oncology & carcinogenesisCancer researchbiology.proteinDisease ProgressionSettore BIO/14 - FarmacologiaSuppressorbusinessFunction (biology)
researchProduct

IL-34–Dependent Intrarenal and Systemic Mechanisms Promote Lupus Nephritis in MRL-Faslpr Mice

2019

Background In people with SLE and in the MRL- Fas lpr lupus mouse model, macrophages and autoantibodies are central to lupus nephritis. IL-34 mediates macrophage survival and proliferation, is expressed by tubular epithelial cells (TECs), and binds to the cFMS receptor on macrophages and to a newly identified second receptor, PTPRZ. Methods To investigate whether IL-34–dependent intrarenal and systemic mechanisms promote lupus nephritis, we compared lupus nephritis and systemic illness in MRL- Fas lpr mice expressing IL-34 and IL-34 knockout (KO) MRL- Fas lpr mice. We also assessed expression of IL-34 and the cFMS and PTPRZ receptors in patients with lupus nephritis. Results Intrarenal IL-3…

0301 basic medicineMice Inbred MRL lprChemokineCell SurvivalLupus nephritisRisk AssessmentMonocytesMice03 medical and health sciences0302 clinical medicineSpecies Specificityimmune system diseasesmedicineAnimalsMacrophageMolecular Targeted Therapyskin and connective tissue diseasesCells CulturedCell ProliferationMice KnockoutSystemic lupus erythematosusCell Deathbiologybusiness.industryInterleukinsMacrophagesGeneral MedicineMonocyte proliferationmedicine.diseaseLupus NephritisMice Inbred C57BLDisease Models AnimalBasic ResearchKidney Tubules030104 developmental biologyGene Expression RegulationNephrology030220 oncology & carcinogenesisImmunologyKnockout mouseDisease Progressionbiology.proteinChemokinesbusinessMacrophage proliferationNephritisJournal of the American Society of Nephrology
researchProduct